APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Chemotherapy-induced Nausea and Vomiting Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Chemotherapy-induced Nausea and Vomiting Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 173976980322 December 2025191 pages

Choose your research edition.

Industry ResearchChemotherapy-induced Nausea and Vomiting Drugs Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal Chemotherapy-induced Nausea and Vomiting Drugs Industry Growth and Trends Forecast to 2032108 pages · $3,450 USDMarket StructureGlobal Chemotherapy-induced Nausea and Vomiting Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Chemotherapy-induced Nausea and Vomiting Drugs Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Chemotherapy-induced Nausea and Vomiting Drugs Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Chemotherapy-induced Nausea and Vomiting Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Chemotherapy-induced Nausea and Vomiting Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Chemotherapy-induced Nausea and Vomiting Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Chemotherapy-induced Nausea and Vomiting Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Chemotherapy-induced Nausea and Vomiting Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Chemotherapy-induced Nausea and Vomiting Drugs include Eisai, Teva, Novartis, Merck, Mylan, Roche, Tesaro, Qilu Pharma and Mundipharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Chemotherapy-induced Nausea and Vomiting Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Chemotherapy-induced Nausea and Vomiting Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Chemotherapy-induced Nausea and Vomiting Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Chemotherapy-induced Nausea and Vomiting Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Chemotherapy-induced Nausea and Vomiting Drugs Segment by Company

Eisai

Teva

Novartis

Merck

Mylan

Roche

Tesaro

Qilu Pharma

Mundipharma

Heron Therapeutics

Chemotherapy-induced Nausea and Vomiting Drugs Segment by Type

5-HT3 Inhibitors

NK1 Inhibitors

Other

Chemotherapy-induced Nausea and Vomiting Drugs Segment by Application

Moderately Emetogenic Chemotherapy

Highly Emetogenic Chemotherapy

Low Emetogenic Chemotherapy

Other

Chemotherapy-induced Nausea and Vomiting Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Chemotherapy-induced Nausea and Vomiting Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Chemotherapy-induced Nausea and Vomiting Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Chemotherapy-induced Nausea and Vomiting Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Chemotherapy-induced Nausea and Vomiting Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Chemotherapy-induced Nausea and Vomiting Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Chemotherapy-induced Nausea and Vomiting Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Chemotherapy-induced Nausea and Vomiting Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Chemotherapy-induced Nausea and Vomiting Drugs Industry Trends Table 2. Chemotherapy-induced Nausea and Vomiting Drugs Industry Drivers Table 3. Chemotherapy-induced Nausea and Vomiting Drugs Industry Opportunities and Challenges Table 4. Chemotherapy-induced Nausea and Vomiting Drugs Industry Restraints Table 5. Global Chemotherapy-induced Nausea and Vomiting Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Chemotherapy-induced Nausea and Vomiting Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Market Share by Manufacturers Table 9. Global Chemotherapy-induced Nausea and Vomiting Drugs Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Chemotherapy-induced Nausea and Vomiting Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Chemotherapy-induced Nausea and Vomiting Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Chemotherapy-induced Nausea and Vomiting Drugs Manufacturers, Product Type & Application Table 13. Global Chemotherapy-induced Nausea and Vomiting Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Chemotherapy-induced Nausea and Vomiting Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of 5-HT3 Inhibitors Table 17. Major Manufacturers of NK1 Inhibitors Table 18. Major Manufacturers of Other Table 19. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales by Type (2021-2026) & (k units) Table 21. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales by Type (2027-2032) & (k units) Table 22. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Market Share by Type (2021-2026) Table 23. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Market Share by Type (2027-2032) Table 24. Global Chemotherapy-induced Nausea and Vomiting Drugs Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 25. Global Chemotherapy-induced Nausea and Vomiting Drugs Revenue by Type (2021-2026) & (k units) Table 26. Global Chemotherapy-induced Nausea and Vomiting Drugs Revenue by Type (2027-2032) & (k units) Table 27. Global Chemotherapy-induced Nausea and Vomiting Drugs Revenue Market Share by Type (2021-2026) Table 28. Global Chemotherapy-induced Nausea and Vomiting Drugs Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Moderately Emetogenic Chemotherapy Table 30. Major Manufacturers of Highly Emetogenic Chemotherapy Table 31. Major Manufacturers of Low Emetogenic Chemotherapy Table 32. Major Manufacturers of Other Table 33. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales by Application 2021 VS 2025 VS 2032 (k units) Table 34. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales by Application (2021-2026) & (k units) Table 35. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales by Application (2027-2032) & (k units) Table 36. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Market Share by Application (2021-2026) Table 37. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Market Share by Application (2027-2032) Table 38. Global Chemotherapy-induced Nausea and Vomiting Drugs Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 39. Global Chemotherapy-induced Nausea and Vomiting Drugs Revenue by Application (2021-2026) & (k units) Table 40. Global Chemotherapy-induced Nausea and Vomiting Drugs Revenue by Application (2027-2032) & (k units) Table 41. Global Chemotherapy-induced Nausea and Vomiting Drugs Revenue Market Share by Application (2021-2026) Table 42. Global Chemotherapy-induced Nausea and Vomiting Drugs Revenue Market Share by Application (2027-2032) Table 43. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 44. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales by Region (2021-2026) & (k units) Table 45. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Market Share by Region (2021-2026) Table 46. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Forecasted by Region (2027-2032) & (k units) Table 47. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Forecasted Market Share by Region (2027-2032) Table 48. North America Chemotherapy-induced Nausea and Vomiting Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 49. North America Chemotherapy-induced Nausea and Vomiting Drugs Sales by Country (2021-2026) & (k units) Table 50. North America Chemotherapy-induced Nausea and Vomiting Drugs Sales by Country (2027-2032) & (k units) Table 51. Europe Chemotherapy-induced Nausea and Vomiting Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 52. Europe Chemotherapy-induced Nausea and Vomiting Drugs Sales by Country (2021-2026) & (k units) Table 53. Europe Chemotherapy-induced Nausea and Vomiting Drugs Sales by Country (2027-2032) & (k units) Table 54. Asia Pacific Chemotherapy-induced Nausea and Vomiting Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 55. Asia Pacific Chemotherapy-induced Nausea and Vomiting Drugs Sales by Country (2021-2026) & (k units) Table 56. Asia Pacific Chemotherapy-induced Nausea and Vomiting Drugs Sales by Country (2027-2032) & (k units) Table 57. South America, Middle East and Africa Chemotherapy-induced Nausea and Vomiting Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 58. South America, Middle East and Africa Chemotherapy-induced Nausea and Vomiting Drugs Sales by Country (2021-2026) & (k units) Table 59. South America, Middle East and Africa Chemotherapy-induced Nausea and Vomiting Drugs Sales by Country (2027-2032) & (k units) Table 60. Global Chemotherapy-induced Nausea and Vomiting Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Chemotherapy-induced Nausea and Vomiting Drugs Revenue by Region (2021-2026) & (US$ Million) Table 62. Global Chemotherapy-induced Nausea and Vomiting Drugs Revenue by Region (2027-2032) & (US$ Million) Table 63. Global Chemotherapy-induced Nausea and Vomiting Drugs Revenue Market Share by Region (2021-2026) Table 64. Global Chemotherapy-induced Nausea and Vomiting Drugs Revenue Market Share by Region (2027-2032) Table 65. Eisai Company Information Table 66. Eisai Business Overview Table 67. Eisai Chemotherapy-induced Nausea and Vomiting Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Eisai Chemotherapy-induced Nausea and Vomiting Drugs Product Portfolio Table 69. Eisai Recent Development Table 70. Teva Company Information Table 71. Teva Business Overview Table 72. Teva Chemotherapy-induced Nausea and Vomiting Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Teva Chemotherapy-induced Nausea and Vomiting Drugs Product Portfolio Table 74. Teva Recent Development Table 75. Novartis Company Information Table 76. Novartis Business Overview Table 77. Novartis Chemotherapy-induced Nausea and Vomiting Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Novartis Chemotherapy-induced Nausea and Vomiting Drugs Product Portfolio Table 79. Novartis Recent Development Table 80. Merck Company Information Table 81. Merck Business Overview Table 82. Merck Chemotherapy-induced Nausea and Vomiting Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Merck Chemotherapy-induced Nausea and Vomiting Drugs Product Portfolio Table 84. Merck Recent Development Table 85. Mylan Company Information Table 86. Mylan Business Overview Table 87. Mylan Chemotherapy-induced Nausea and Vomiting Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Mylan Chemotherapy-induced Nausea and Vomiting Drugs Product Portfolio Table 89. Mylan Recent Development Table 90. Roche Company Information Table 91. Roche Business Overview Table 92. Roche Chemotherapy-induced Nausea and Vomiting Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. Roche Chemotherapy-induced Nausea and Vomiting Drugs Product Portfolio Table 94. Roche Recent Development Table 95. Tesaro Company Information Table 96. Tesaro Business Overview Table 97. Tesaro Chemotherapy-induced Nausea and Vomiting Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 98. Tesaro Chemotherapy-induced Nausea and Vomiting Drugs Product Portfolio Table 99. Tesaro Recent Development Table 100. Qilu Pharma Company Information Table 101. Qilu Pharma Business Overview Table 102. Qilu Pharma Chemotherapy-induced Nausea and Vomiting Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 103. Qilu Pharma Chemotherapy-induced Nausea and Vomiting Drugs Product Portfolio Table 104. Qilu Pharma Recent Development Table 105. Mundipharma Company Information Table 106. Mundipharma Business Overview Table 107. Mundipharma Chemotherapy-induced Nausea and Vomiting Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 108. Mundipharma Chemotherapy-induced Nausea and Vomiting Drugs Product Portfolio Table 109. Mundipharma Recent Development Table 110. Heron Therapeutics Company Information Table 111. Heron Therapeutics Business Overview Table 112. Heron Therapeutics Chemotherapy-induced Nausea and Vomiting Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 113. Heron Therapeutics Chemotherapy-induced Nausea and Vomiting Drugs Product Portfolio Table 114. Heron Therapeutics Recent Development Table 115. Key Raw Materials Table 116. Raw Materials Key Suppliers Table 117. Chemotherapy-induced Nausea and Vomiting Drugs Distributors List Table 118. Chemotherapy-induced Nausea and Vomiting Drugs Customers List Table 119. Research Programs/Design for This Report Table 120. Authors List of This Report Table 121. Secondary Sources Table 122. Primary Sources List of Figures Figure 1. Chemotherapy-induced Nausea and Vomiting Drugs Product Image Figure 2. Global Chemotherapy-induced Nausea and Vomiting Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Chemotherapy-induced Nausea and Vomiting Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales (2021-2032) & (k units) Figure 5. Global Chemotherapy-induced Nausea and Vomiting Drugs Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Chemotherapy-induced Nausea and Vomiting Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. 5-HT3 Inhibitors Image Figure 9. NK1 Inhibitors Image Figure 10. Other Image Figure 11. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Market Share by Type (2021-2032) Figure 14. Global Chemotherapy-induced Nausea and Vomiting Drugs Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 15. Global Chemotherapy-induced Nausea and Vomiting Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Chemotherapy-induced Nausea and Vomiting Drugs Revenue Market Share by Type (2021-2032) Figure 17. Moderately Emetogenic Chemotherapy Image Figure 18. Highly Emetogenic Chemotherapy Image Figure 19. Low Emetogenic Chemotherapy Image Figure 20. Other Image Figure 21. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 22. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 23. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Market Share by Application (2021-2032) Figure 24. Global Chemotherapy-induced Nausea and Vomiting Drugs Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 25. Global Chemotherapy-induced Nausea and Vomiting Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 26. Global Chemotherapy-induced Nausea and Vomiting Drugs Revenue Market Share by Application (2021-2032) Figure 27. North America Chemotherapy-induced Nausea and Vomiting Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 28. North America Chemotherapy-induced Nausea and Vomiting Drugs Sales Market Share by Country (2021-2032) Figure 29. U.S. Chemotherapy-induced Nausea and Vomiting Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 30. Canada Chemotherapy-induced Nausea and Vomiting Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 31. Mexico Chemotherapy-induced Nausea and Vomiting Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 32. Europe Chemotherapy-induced Nausea and Vomiting Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 33. Europe Chemotherapy-induced Nausea and Vomiting Drugs Sales Market Share by Country (2021-2032) Figure 34. Germany Chemotherapy-induced Nausea and Vomiting Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 35. France Chemotherapy-induced Nausea and Vomiting Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 36. U.K. Chemotherapy-induced Nausea and Vomiting Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 37. Italy Chemotherapy-induced Nausea and Vomiting Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 38. Netherlands Chemotherapy-induced Nausea and Vomiting Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 39. Asia Pacific Chemotherapy-induced Nausea and Vomiting Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 40. Asia Pacific Chemotherapy-induced Nausea and Vomiting Drugs Sales Market Share by Country (2021-2032) Figure 41. China Chemotherapy-induced Nausea and Vomiting Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 42. Japan Chemotherapy-induced Nausea and Vomiting Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 43. South Korea Chemotherapy-induced Nausea and Vomiting Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 44. Southeast Asia Chemotherapy-induced Nausea and Vomiting Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 45. India Chemotherapy-induced Nausea and Vomiting Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 46. Australia Chemotherapy-induced Nausea and Vomiting Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 47. South America, Middle East and Africa Chemotherapy-induced Nausea and Vomiting Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 48. South America, Middle East and Africa Chemotherapy-induced Nausea and Vomiting Drugs Sales Market Share by Country (2021-2032) Figure 49. Brazil Chemotherapy-induced Nausea and Vomiting Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 50. South Africa Chemotherapy-induced Nausea and Vomiting Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 51. Saudi Arabia Chemotherapy-induced Nausea and Vomiting Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 52. Turkey Chemotherapy-induced Nausea and Vomiting Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 53. Argentina Chemotherapy-induced Nausea and Vomiting Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 54. UAE Chemotherapy-induced Nausea and Vomiting Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 55. Egypt Chemotherapy-induced Nausea and Vomiting Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 56. Chile Chemotherapy-induced Nausea and Vomiting Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 57. Global Chemotherapy-induced Nausea and Vomiting Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Global Chemotherapy-induced Nausea and Vomiting Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 59. North America Chemotherapy-induced Nausea and Vomiting Drugs Revenue (2021-2032) & (US$ Million) Figure 60. North America Chemotherapy-induced Nausea and Vomiting Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe Chemotherapy-induced Nausea and Vomiting Drugs Revenue (2021-2032) & (US$ Million) Figure 62. Europe Chemotherapy-induced Nausea and Vomiting Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific Chemotherapy-induced Nausea and Vomiting Drugs Revenue (2021-2032) & (US$ Million) Figure 64. Asia-Pacific Chemotherapy-induced Nausea and Vomiting Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. South America, Middle East and Africa Chemotherapy-induced Nausea and Vomiting Drugs Revenue (2021-2032) & (US$ Million) Figure 66. South America, Middle East and Africa Chemotherapy-induced Nausea and Vomiting Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Chemotherapy-induced Nausea and Vomiting Drugs Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Chemotherapy-induced Nausea and Vomiting Drugs Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • 5-HT3 Inhibitors
  • NK1 Inhibitors
  • Other
Applications
  • Moderately Emetogenic Chemotherapy
  • Highly Emetogenic Chemotherapy
  • Low Emetogenic Chemotherapy
  • Other
Companies covered
  • Eisai
  • Teva
  • Novartis
  • Merck
  • Mylan
  • Roche
  • Tesaro
  • Qilu Pharma
  • Mundipharma
  • Heron Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Chemotherapy-induced Nausea and Vomiting Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Chemotherapy-induced Nausea and Vomiting Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Chemotherapy-induced Nausea and Vomiting Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Chemotherapy-induced Nausea and Vomiting Drugs Market Dynamics
  1. 2.1 Chemotherapy-induced Nausea and Vomiting Drugs Industry Trends
  2. 2.2 Chemotherapy-induced Nausea and Vomiting Drugs Industry Drivers
  3. 2.3 Chemotherapy-induced Nausea and Vomiting Drugs Industry Opportunities and Challenges
  4. 2.4 Chemotherapy-induced Nausea and Vomiting Drugs Industry Restraints
3 Chemotherapy-induced Nausea and Vomiting Drugs Market by Manufacturers
  1. 3.1 Global Chemotherapy-induced Nausea and Vomiting Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global Chemotherapy-induced Nausea and Vomiting Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Chemotherapy-induced Nausea and Vomiting Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Chemotherapy-induced Nausea and Vomiting Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Chemotherapy-induced Nausea and Vomiting Drugs Manufacturers, Product Type & Application
  7. 3.7 Global Chemotherapy-induced Nausea and Vomiting Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Chemotherapy-induced Nausea and Vomiting Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Chemotherapy-induced Nausea and Vomiting Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Chemotherapy-induced Nausea and Vomiting Drugs Tier 1, Tier 2, and Tier 3
4 Chemotherapy-induced Nausea and Vomiting Drugs Market by Type
  1. 4.1 Chemotherapy-induced Nausea and Vomiting Drugs Type Introduction
  2. 4.1.1 5-HT3 Inhibitors
  3. 4.1.2 NK1 Inhibitors
  4. 4.1.3 Other
  5. 4.2 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales by Type
  6. 4.2.1 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales by Type (2021-2032)
  8. 4.2.3 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Market Share by Type (2021-2032)
  9. 4.3 Global Chemotherapy-induced Nausea and Vomiting Drugs Revenue by Type
  10. 4.3.1 Global Chemotherapy-induced Nausea and Vomiting Drugs Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Chemotherapy-induced Nausea and Vomiting Drugs Revenue by Type (2021-2032)
  12. 4.3.3 Global Chemotherapy-induced Nausea and Vomiting Drugs Revenue Market Share by Type (2021-2032)
5 Chemotherapy-induced Nausea and Vomiting Drugs Market by Application
  1. 5.1 Chemotherapy-induced Nausea and Vomiting Drugs Application Introduction
  2. 5.1.1 Moderately Emetogenic Chemotherapy
  3. 5.1.2 Highly Emetogenic Chemotherapy
  4. 5.1.3 Low Emetogenic Chemotherapy
  5. 5.1.4 Other
  6. 5.2 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales by Application
  7. 5.2.1 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales by Application (2021-2032)
  9. 5.2.3 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Market Share by Application (2021-2032)
  10. 5.3 Global Chemotherapy-induced Nausea and Vomiting Drugs Revenue by Application
  11. 5.3.1 Global Chemotherapy-induced Nausea and Vomiting Drugs Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Chemotherapy-induced Nausea and Vomiting Drugs Revenue by Application (2021-2032)
  13. 5.3.3 Global Chemotherapy-induced Nausea and Vomiting Drugs Revenue Market Share by Application (2021-2032)
6 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales by Region
  1. 6.1 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Chemotherapy-induced Nausea and Vomiting Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Chemotherapy-induced Nausea and Vomiting Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Chemotherapy-induced Nausea and Vomiting Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Chemotherapy-induced Nausea and Vomiting Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Chemotherapy-induced Nausea and Vomiting Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Chemotherapy-induced Nausea and Vomiting Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Chemotherapy-induced Nausea and Vomiting Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Chemotherapy-induced Nausea and Vomiting Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Chemotherapy-induced Nausea and Vomiting Drugs Revenue by Region
  1. 7.1 Global Chemotherapy-induced Nausea and Vomiting Drugs Revenue by Region
  2. 7.1.1 Global Chemotherapy-induced Nausea and Vomiting Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Chemotherapy-induced Nausea and Vomiting Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global Chemotherapy-induced Nausea and Vomiting Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global Chemotherapy-induced Nausea and Vomiting Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Chemotherapy-induced Nausea and Vomiting Drugs Revenue (2021-2032)
  8. 7.2.2 North America Chemotherapy-induced Nausea and Vomiting Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Chemotherapy-induced Nausea and Vomiting Drugs Revenue (2021-2032)
  11. 7.3.2 Europe Chemotherapy-induced Nausea and Vomiting Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Chemotherapy-induced Nausea and Vomiting Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Chemotherapy-induced Nausea and Vomiting Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Chemotherapy-induced Nausea and Vomiting Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Chemotherapy-induced Nausea and Vomiting Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Eisai
  2. 8.1.1 Eisai Company Information
  3. 8.1.2 Eisai Business Overview
  4. 8.1.3 Eisai Chemotherapy-induced Nausea and Vomiting Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Eisai Chemotherapy-induced Nausea and Vomiting Drugs Product Portfolio
  6. 8.1.5 Eisai Recent Developments
  7. 8.2 Teva
  8. 8.2.1 Teva Company Information
  9. 8.2.2 Teva Business Overview
  10. 8.2.3 Teva Chemotherapy-induced Nausea and Vomiting Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Teva Chemotherapy-induced Nausea and Vomiting Drugs Product Portfolio
  12. 8.2.5 Teva Recent Developments
  13. 8.3 Novartis
  14. 8.3.1 Novartis Company Information
  15. 8.3.2 Novartis Business Overview
  16. 8.3.3 Novartis Chemotherapy-induced Nausea and Vomiting Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Novartis Chemotherapy-induced Nausea and Vomiting Drugs Product Portfolio
  18. 8.3.5 Novartis Recent Developments
  19. 8.4 Merck
  20. 8.4.1 Merck Company Information
  21. 8.4.2 Merck Business Overview
  22. 8.4.3 Merck Chemotherapy-induced Nausea and Vomiting Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Merck Chemotherapy-induced Nausea and Vomiting Drugs Product Portfolio
  24. 8.4.5 Merck Recent Developments
  25. 8.5 Mylan
  26. 8.5.1 Mylan Company Information
  27. 8.5.2 Mylan Business Overview
  28. 8.5.3 Mylan Chemotherapy-induced Nausea and Vomiting Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Mylan Chemotherapy-induced Nausea and Vomiting Drugs Product Portfolio
  30. 8.5.5 Mylan Recent Developments
  31. 8.6 Roche
  32. 8.6.1 Roche Company Information
  33. 8.6.2 Roche Business Overview
  34. 8.6.3 Roche Chemotherapy-induced Nausea and Vomiting Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Roche Chemotherapy-induced Nausea and Vomiting Drugs Product Portfolio
  36. 8.6.5 Roche Recent Developments
  37. 8.7 Tesaro
  38. 8.7.1 Tesaro Company Information
  39. 8.7.2 Tesaro Business Overview
  40. 8.7.3 Tesaro Chemotherapy-induced Nausea and Vomiting Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Tesaro Chemotherapy-induced Nausea and Vomiting Drugs Product Portfolio
  42. 8.7.5 Tesaro Recent Developments
  43. 8.8 Qilu Pharma
  44. 8.8.1 Qilu Pharma Company Information
  45. 8.8.2 Qilu Pharma Business Overview
  46. 8.8.3 Qilu Pharma Chemotherapy-induced Nausea and Vomiting Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Qilu Pharma Chemotherapy-induced Nausea and Vomiting Drugs Product Portfolio
  48. 8.8.5 Qilu Pharma Recent Developments
  49. 8.9 Mundipharma
  50. 8.9.1 Mundipharma Company Information
  51. 8.9.2 Mundipharma Business Overview
  52. 8.9.3 Mundipharma Chemotherapy-induced Nausea and Vomiting Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Mundipharma Chemotherapy-induced Nausea and Vomiting Drugs Product Portfolio
  54. 8.9.5 Mundipharma Recent Developments
  55. 8.10 Heron Therapeutics
  56. 8.10.1 Heron Therapeutics Company Information
  57. 8.10.2 Heron Therapeutics Business Overview
  58. 8.10.3 Heron Therapeutics Chemotherapy-induced Nausea and Vomiting Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Heron Therapeutics Chemotherapy-induced Nausea and Vomiting Drugs Product Portfolio
  60. 8.10.5 Heron Therapeutics Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Chemotherapy-induced Nausea and Vomiting Drugs Value Chain Analysis
  2. 9.1.1 Chemotherapy-induced Nausea and Vomiting Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Chemotherapy-induced Nausea and Vomiting Drugs Production Mode & Process
  6. 9.2 Chemotherapy-induced Nausea and Vomiting Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Chemotherapy-induced Nausea and Vomiting Drugs Distributors
  9. 9.2.3 Chemotherapy-induced Nausea and Vomiting Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst